Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity

Carla Valsecchi, Maribel Mirabet, Ilaria Mancini, Marina Biganzoli, Lucia Schiavone, Susanna Faraudo, Daniel Mane-Padros, David Giles, Josep Serra-Domenech, Silvia Blanch, Silvia Maria Trisolini, Luca Facchini, Erminia Rinaldi, Flora Peyvandi

Research output: Contribution to journalArticle

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy (TMA) characterized by the severe deficiency of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (< 10%). Rapid ADAMTS13 testing is crucial for an early diagnosis and optimal management of acute TTP. We evaluated the performance of the HemosIL AcuStar ADAMTS13 activity assay (Instrumentation Laboratory, Bedford, Massachusetts, United States), a fully automated chemiluminescent immunoassay with an analytical time of 33 minutes. A method comparison study was performed on 176 samples from 49 healthy donors and 127 TMA patients (109 TTP, 7 atypical hemolytic uremic syndrome, 11 other TMAs), comparing this new assay with an in-house FRETS-VWF73 assay and a commercial enzyme-linked immunosorbent assay (ELISA) (TECHNOZYM ADAMTS-13 Activity, Technoclone GmbH, Vienna, Austria). Agreement between methods was assessed with focus on ADAMTS13 activity less than 10%, the medical decision level relevant for TTP diagnosis. The HemosIL AcuStar ADAMTS13 Activity showed good correlation with both the FRETS-VWF73 (r = 0.96) and ELISA (r = 0.96) methods. Slope of the Passing-Bablok regression was 1.05 for FRETS-VWF73 and 1.02 for ELISA, and absolute bias at the medical decision level was +0.1 and +0.3%, respectively. The study also revealed high agreement with FRETS-VWF73 (kappa 0.97) and ELISA (kappa 0.98) methods in classifying TTP patients with a severe deficiency of ADAMTS13 activity. Because of its short turnaround time and full automation, the HemosIL AcuStar ADAMTS13 activity assay might become the assay of choice to rapidly test ADAMTS13 activity in plasma and thus establish the diagnosis of acute TTP in emergency settings.

Original languageEnglish
Pages (from-to)1767-1772
Number of pages6
JournalThrombosis and Haemostasis
Volume119
Issue number11
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • ADAMTS/ADAMTS13
  • autoimmune diseases
  • chemiluminescent assay
  • diagnosis management
  • thrombotic thrombocytopenic purpura (TTP/HUS)

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity'. Together they form a unique fingerprint.

  • Cite this

    Valsecchi, C., Mirabet, M., Mancini, I., Biganzoli, M., Schiavone, L., Faraudo, S., Mane-Padros, D., Giles, D., Serra-Domenech, J., Blanch, S., Trisolini, S. M., Facchini, L., Rinaldi, E., & Peyvandi, F. (2019). Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity. Thrombosis and Haemostasis, 119(11), 1767-1772. https://doi.org/10.1055/s-0039-1696718